Heart, Lung and Circulation最新文献

{"title":"Platelet Count Drop After Aortic Valve Bioprostheses Implantation: Short and Long-Term Outcomes","authors":"Anna Olasińska-Wiśniewska MD, PhD, FESC ,&nbsp;Bartłomiej Perek MD, PhD ,&nbsp;Michał Bociański MD ,&nbsp;Tomasz Urbanowicz MD, PhD, FESC ,&nbsp;Marcin Misterski MD, PhD ,&nbsp;Mateusz Puślecki MD, PhD ,&nbsp;Piotr Buczkowski MD, PhD ,&nbsp;Jan Kaczmarek ,&nbsp;Paweł Marcinkowski MD ,&nbsp;Sebastian Stefaniak MD, PhD ,&nbsp;Marek Grygier MD, PhD, FESC ,&nbsp;Marek Jemielity MD, PhD","doi":"10.1016/j.hlc.2025.05.097","DOIUrl":"10.1016/j.hlc.2025.05.097","url":null,"abstract":"<div><h3>Background</h3><div>Surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) have evolved significantly in recent years. Postoperative thrombocytopenia has been observed after both techniques. The study aimed to assess if postprocedural platelet count drop (PCD) influenced early results and 1-year survival in patients treated with SAVR and TAVI. The secondary aim was to compare the degrees of PCD between techniques.</div></div><div><h3>Method</h3><div>The retrospective single-centre study involved patients treated for symptomatic aortic stenosis. Periprocedural platelet count characteristic was evaluated. One-year mortality was assessed.</div></div><div><h3>Results</h3><div>The study group consisted of 313 patients, including the Perceval group (n=73), the Resilia group (n=17), the TAVI group treated between 2013 and 2017 (n=140), and with newer bioprostheses implanted between May 2021 and July 2022 (n=83). Baseline platelet count did not differ between groups (p=0.116). All patients, apart from two (both in the TAVI groups), presented with any postprocedural PCD. The most prominent PCD in all groups was observed on the second and third postoperative days but was the most pronounced in the Perceval prosthesis group (p&lt;0.001), with PCD &gt;50% in 66 patients (90.4%). Twenty-two (22) patients died during the first postoperative year, five in the new TAVI, 12 in the early TAVI, and five in the Perceval groups. Patients who died did not differ significantly in PCD value compared with 1-year survivors in all study groups. A probability of 1-year survival according to the Kaplan-Meier curve was comparable between the studied groups (p=0.793). Early TAVI patients with PCD &gt;50% were burdened with a higher risk of complications, including bleeding complications (p=0.032), blood transfusion (p=0.04), and acute kidney injury (p=0.005).</div></div><div><h3>Conclusions</h3><div>Thrombocytopenia is a common phenomenon in patients treated with TAVI and SAVR but has no impact on 1-year survival. The implantation of newer models of bioprostheses, both transcatheter and surgical, is associated with a smaller decrease in platelet counts.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Pages 1257-1269"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subtle ECG, but Significant Angiographic Change: Aslanger’s Pattern, a Newly Described STEMI - Equivalent","authors":"Thomas Barlow MD ,&nbsp;Harry C. Lowe PhD, FRACP","doi":"10.1016/j.hlc.2025.04.090","DOIUrl":"10.1016/j.hlc.2025.04.090","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Pages e161-e163"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Outcomes of Transcatheter Edge-to-Edge Repair With Early Versus Latest Generation MitraClip for Severe Mitral Regurgitation","authors":"Khin May Thaw MBBS ,&nbsp;William Scalia MBBS ,&nbsp;Ronan Petersen MBBS ,&nbsp;Su Hnin Hlaing FRACP ,&nbsp;Michael Savage PhD ,&nbsp;Dale Murdoch BSc, FRACP ,&nbsp;Karl Poon FRACP ,&nbsp;O. Christopher Raffel MBChB, FRACP, FPICS ,&nbsp;Katherine Lau FRACP ,&nbsp;Stephen Tomlinson FRACP ,&nbsp;Lisa Walters FRACP ,&nbsp;Gregory Scalia FRACP, FASE ,&nbsp;Darren L. Walters FRACP, FSCAI","doi":"10.1016/j.hlc.2025.06.1033","DOIUrl":"10.1016/j.hlc.2025.06.1033","url":null,"abstract":"<div><h3>Background</h3><div>The fourth-generation MitraClip G4 system is the latest version of the transcatheter edge-to-edge repair (TEER) system for mitral regurgitation (MR).</div></div><div><h3>Aim</h3><div>This study aimed to evaluate the effectiveness of the MitraClip G4 in the reduction of MR compared to the early-generation MitraClip.</div></div><div><h3>Method</h3><div>We performed a retrospective analysis of consecutive patients undergoing TEER for MR with either the early-generation or newer-generation MitraClip G4 from a single-centre registry. Baseline patient characteristics and echocardiographic data were compared between groups.</div></div><div><h3>Results</h3><div>Between December 2011 and February 2024, a total of 183 patients underwent mitral TEER. Of these, 140 patients were treated with early-generation MitraClip, and 43 patients were treated with the G4 system. Reduction of MR to grade≤1 was achieved in 59.5% of patients treated with the G4 MitraClip compared to 25.7% in the early-generation cohort (p&lt;0.001). There was a significant reduction in median MR severity post-TEER in the G4 cohort compared to the early-generation group (p=0.006) (median change: 3 grades in the G4 group). There was no significant difference in post-TEER (moderate or severe) mitral stenosis (p=0.743). No significant difference was noted in the median number of clips used. No significant difference was noted in baseline characteristics, although a proportionally higher number of previous coronary interventions and coronary artery bypass grafts were observed in the early-generation MitraClip group.</div></div><div><h3>Conclusions</h3><div>The MitraClip G4 system achieved significantly greater reduction of MR severity compared to the earlier generation mitral TEER device.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Pages 1228-1234"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying the CSANZ Expert Position Statement on Appropriate Training for AF Ablation: Mentoring for Qualified Electrophysiologists Adopting New Techniques","authors":"Peter M. Kistler MBBS, PhD, FRACP ,&nbsp;Prashanthan Sanders MBBS, PhD, FRACP ,&nbsp;Stuart P. Thomas MBBS, PhD, FRACP ,&nbsp;Jonathan M. Kalman MBBS, PhD, FRACP ,&nbsp;2023 CSANZ Expert Position Statement authors","doi":"10.1016/j.hlc.2025.08.011","DOIUrl":"10.1016/j.hlc.2025.08.011","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Page e160"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology, Surgical Management and Mortality of Thoracic Aortic Disease in Australia: A 10-Year Population-Based Study","authors":"Geoffrey D. Lester MBBS, MPH, MPhil ,&nbsp;Richmond W. Jeremy MBBS, PhD","doi":"10.1016/j.hlc.2025.04.087","DOIUrl":"10.1016/j.hlc.2025.04.087","url":null,"abstract":"<div><h3>Aim</h3><div>Thoracic aortic disease (TAD) is a life-threatening condition with high morbidity and mortality. Australia lacks comprehensive published national data on TAD epidemiology, outcomes, and management. The aim of this study is to estimate the nationwide burden of TAD through hospitalisation, mortality, and surgical interventions.</div></div><div><h3>Methods</h3><div>A retrospective cohort study analysed hospital admissions for TAD in Australia from 2010 to 2020 using International Classification of Diseases data from the Australian Institute of Health and Welfare. Admissions were stratified by age, sex, and diagnosis, with incidence rates adjusted for population metrics. Surgical data were correlated with thoracic aortic repair codes, and mortality was estimated using hospital and national statistics. The Sydney Local Health District Research Committee granted ethics approval.</div></div><div><h3>Results</h3><div>Between 2010 and 2020, 16,738 TAD admissions occurred, with 63.3% male. Annual admissions rose significantly from 1,235 to 2,122 (p<em>&lt;</em>0.01). The average incidence was 8.9 per 100,000 males and 5.2 per 100,000 females. Thoracic cases increased by 62% relative to abdominal cases, with a 65% rise in mortality (p<em>&lt;</em>0.01). Males underwent surgery 32% more frequently than females (p<em>&lt;</em>0.001). TAD patients stay in the hospital eight times longer than the population mean. Ten-year mortality was approximately 3,128 deaths, with an annual population TAD mortality rate of 0.015%.</div></div><div><h3>Conclusions</h3><div>The growing burden of TAD diagnosis in Australia underscores the need for enhanced surveillance and targeted healthcare strategies. Rising admissions, prolonged hospitalisation, and worse female outcomes highlight significant gaps in TAD recognition and management.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Pages 1270-1280"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Sex Affect the Efficacy, Safety, and Quality of Life Outcomes for Patients Using Angiotensin Receptor Neprilysin Inhibitor, Soluble Guanylate Cyclase Stimulators, and Cardiac Myosin Activators in Heart Failure? A Systematic Review","authors":"Amanda Veiga Barbosa MSc ,&nbsp;Lucas Caetano Araújo Silva MSc ,&nbsp;Inajara Rotta PhD ,&nbsp;Patricia Melo Aguiar PhD","doi":"10.1016/j.hlc.2025.04.082","DOIUrl":"10.1016/j.hlc.2025.04.082","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure (HF) is a condition with significant differences between men and women, due to pathophysiology disparities attributed to hormonal factors and different comorbidities rates. There are no guidelines specifically tailored for women. The objective of the study is to summarise the current evidence of efficacy, safety, and impact on quality of life associated with angiotensin receptor neprilysin inhibitor, guanylate cyclase stimulators, and cardiac myosin activators drugs across different sexes.</div></div><div><h3>Methods</h3><div>We performed a systematic search on PubMed, EMBASE, Cochrane Central, and Google Scholar databases for randomised controlled trials (RCTs), including patients with HF with reduced ejection fraction or HF with preserved ejection fraction. The outcomes were N-terminal pro-B-type natriuretic peptide hormone levels, functional capacity, ventricular remodelling, safety results, and quality of life. The risk of bias was assessed using the Risk of Bias 2 tool.</div></div><div><h3>Results</h3><div>This review included data from eight RCTs (10 studies), involving a total of 15,021 patients, of whom 48% were women. HF with preserved ejection fraction was studied in five RCTs, and HF with reduced ejection fraction in three RCTs. Regarding clinical outcomes, six RCTs evaluated N-terminal pro-B-type natriuretic peptide hormone levels, all comparing sacubitril-valsartan with standard therapy, while two others compared functional capacity between the sexes, two analysed safety outcomes by sex subgroups, and only one RCT compared men and women for the ventricular remodelling outcome. Two RCTs assessed differences in quality of life between men and women. None of the studies showed any statistical difference between the subgroups and most outcomes demonstrated a low risk of bias.</div></div><div><h3>Conclusions</h3><div>This review shows consistent efficacy, safety and quality of life across both sexes for HF treatments.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 11","pages":"Pages 1169-1178"},"PeriodicalIF":2.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes and Cardiometabolic Care, Pharmacotherapy, and Patient Outcomes in Two Regional Aboriginal Primary Care Health Centres: Lessons to be Learnt","authors":"Annabelle G. Hayes FRACP ,&nbsp;Odette Pearson BAppHSc, GCert HE, PhD ,&nbsp;Chinmay S. Marathe FRACP ,&nbsp;David Jesudason FRACP, PhD","doi":"10.1016/j.hlc.2025.06.1019","DOIUrl":"10.1016/j.hlc.2025.06.1019","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus (T2DM) affects Aboriginal Australian populations six times more frequently than non-Indigenous Australians, with disparity increasing by remoteness. Contemporary guidelines recommend optimising cardiometabolic care, including achieving a target glycated haemoglobin (HbA1c) &lt;7%, blood pressure &lt;130/80 mmHg, and use of pharmacotherapy, including the maximal tolerated statin dose and consideration of sodium–glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in selected subpopulations.</div></div><div><h3>Aim</h3><div>This study aimed to determine whether cardiometabolic treatment targets and pharmacological management met best practice guidelines in two rural Aboriginal Community Controlled Health Organisations.</div></div><div><h3>Method</h3><div>A retrospective audit of electronic medical records was conducted in two rural Aboriginal Community Controlled Health Organisations between January 2020 and January 2021. Data were collected for people aged over 18 years who regularly attended the clinic, identified as Aboriginal, and had a documented diagnosis of T2DM.</div></div><div><h3>Results</h3><div>A total of 274 patients met the inclusion criteria, 64% of whom were female. The median age of T2DM diagnosis was 44 years (interquartile range 32–50), with a median diabetes duration of 9 years (3–17), HbA1c 8.0% (6.9–9.4), body mass index 31.6 kg/m² (27–36.3), urine albumin–creatinine ratio (ACR) 3.8 mg/mol (1.1–20.0), and mean low density lipoprotein cholesterol 2.1 mmol/L (±0.8). Capture rates were 70% for HbA1c, 51% for urine ACR, and 51% for lipid studies. Among recorded results, 51/193 (26%) of HbA1c were &lt;7%, 80/228 (35%) of blood pressure readings were below 130/80 mmHg. Nephropathy was present in 42% of patients, and obesity in 61%. Clinically significant albuminuria was observed in 69/140 (50%) of patients with available ACR data. Statins were prescribed in 50%, sodium–glucose co-transporter 2 inhibitors in 20%, and glucagon-like peptide-1 receptor agonists in 7% of the population.</div></div><div><h3>Conclusions</h3><div>This study has characterised a population with an early age of T2DM diagnosis, high rates of nephropathy and obesity, and suboptimal glycaemic control. Prescription rates of modern therapies were low. These findings highlight areas for targeted improvement in the quality of cardiometabolic care, including the increased use of modern diabetes agents.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 10","pages":"Pages 1069-1077"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Cardiovascular-Kidney-Metabolic Syndrome Staging on Depression Risk: A National Study","authors":"Bowen Zha MD ,&nbsp;Angshu Cai MD ,&nbsp;Hongrui Yu MD ,&nbsp;Zhexue Wang MD","doi":"10.1016/j.hlc.2025.06.1017","DOIUrl":"10.1016/j.hlc.2025.06.1017","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular-kidney-metabolic (CKM) syndrome, recently defined by the American Heart Association, encompasses cardiovascular disease, chronic kidney disease, and metabolic disorders. However, its association with depression across different stages remains unclear.</div></div><div><h3>Method</h3><div>We analysed 4,097 adults from National Health and Nutrition Examination Survey 2005–2020. Depression was assessed using the Patient Health Questionnaire-9, and CKM stages were classified according to the 2023 American Heart Association guidelines. Survey-weighted multivariable logistic regression was used to examine associations, with subgroup and sensitivity analyses.</div></div><div><h3>Results</h3><div>The odds of depression increased progressively with CKM severity, with the highest risk observed in Stage 4 (odds ratio [OR] 1.112; 95% confidence interval [CI] 1.039–1.190; p=0.003). Significant associations were also found in Stages 2 and 3. Subgroup analyses revealed stronger associations in females (OR 1.180; 95% CI 1.053–1.322; p=0.005), older adults (OR 1.125; 95% CI 1.081–1.171; p&lt;0.001), Mexican Americans (OR 1.260; 95% CI 1.118–1.419; p&lt;0.001), and individuals with low education (OR 1.463; 95% CI 1.302–1.644; p&lt;0.001).</div></div><div><h3>Conclusions</h3><div>Advancing CKM stage is significantly associated with increased depression risk, particularly among vulnerable sociodemographic groups. These findings highlight the need for integrated mental health strategies in managing CKM syndrome.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 10","pages":"Pages 1131-1138"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Connecting the Dots: Hepatic Steatosis as a Central Player in the Choreography of the Liver-Cardiovascular-Kidney-Metabolic Syndrome","authors":"Richard H. Goodheart MD ,&nbsp;Oyekoya T. Ayonrinde PhD, FRACP, FAASLD, FASGE ∗","doi":"10.1016/j.hlc.2025.08.009","DOIUrl":"10.1016/j.hlc.2025.08.009","url":null,"abstract":"<div><div>Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, with a reach extending beyond the liver to include other metabolic syndrome-related disorders. Cardiovascular disease and type 2 diabetes mellitus are recognised non-communicable disorders and often downstream complications of MASLD and share similar risk factors. However, MASLD has not been afforded parity alongside other cardiometabolic non-communicable disorders, including the cardiovascular-kidney-metabolic (CKM) syndrome. Notably, MASLD is an independent risk factor for increased all-cause mortality and cardiovascular disease. This review aims to position MASLD as a central player in lipid metabolism, systemic inflammation, and insulin resistance, which are key features in the pathogenesis of the CKM syndrome.</div><div>MASLD is an integral player enjoining the liver to the CKM syndrome as the liver-CKM syndrome. Increasing interdisciplinary awareness of this will enhance patient care.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 10","pages":"Pages 1050-1059"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Body Size and Obesity on Cardiovascular Haemodynamics and Myocardial Mechanics","authors":"Christine M. Madronio MPH, MPhil ,&nbsp;Shahab Pathan MBBS, MPH ,&nbsp;Gary K.K. Low MBBS, MPH, PhD ,&nbsp;Nishant Nundlall MBBS ,&nbsp;Kathryn Williams MBBS, PhD ,&nbsp;Sally Badorrek MSc, APD ,&nbsp;Michael Devadas MBBS ,&nbsp;Lynette Gallaty BBehavSt, GradDip ,&nbsp;Kedar Madan MBBS ,&nbsp;Han Loh MBBS ,&nbsp;Shiva Ahmad BMedSci, GradDip ,&nbsp;Kazuaki Negishi MSc, MD, PhD ,&nbsp;Faraz Pathan MBBS, PhD","doi":"10.1016/j.hlc.2025.08.014","DOIUrl":"10.1016/j.hlc.2025.08.014","url":null,"abstract":"<div><h3>Background</h3><div>To improve management of cardiovascular-kidney-metabolic syndrome, a better understanding of the early effects of body size on the heart is crucial and remains under investigation, considering the increasing global prevalence of obesity. Most data available on cardiovascular haemodynamics come from echocardiography despite the known challenges in image acquisition in the context of overweight and obesity. Using cardiac magnetic resonance imaging, we aimed to further investigate the effect of body size on cardiac output (CO) and other early imaging biomarkers of cardiovascular disease.</div></div><div><h3>Method</h3><div>Participants including healthy volunteers and individuals with obesity who were planning to undergo bariatric surgery were recruited from two completed studies. The participants underwent cardiac magnetic resonance imaging. Measures of cardiovascular haemodynamics and myocardial mechanics were collected, including CO, stroke volume, heart rate, chamber volumes, and myocardial strain. The relationship of these variables with body size were assessed.</div></div><div><h3>Results</h3><div>A total of 57 participants were recruited (79% female; mean age, 41 years). A positive linear relationship was observed between CO vs body mass index (BMI) (p&lt;0.01) and body surface area (BSA) (p&lt;0.01). A similar trend was seen with stroke volume vs BSA (p&lt;0.01) and BMI (p&lt;0.01). Indexation to BSA rendered chamber volumes similar. We found significant differences in left and right atrial strain between the groups. Regression analysis demonstrated an association between left ventricular global longitudinal strain and right atrial strain with BSA and between left ventricular global longitudinal strain, right ventricular free wall strain, and right atrial strain with BMI.</div></div><div><h3>Conclusions</h3><div>Obesity is associated with increased CO; this increase is a result of cardiac remodelling and consequent increase in stroke volume. Obesity is associated with an impairment of subclinical markers of cardiovascular disease measured using multichamber strain.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 10","pages":"Pages 1109-1118"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}